Rongyu Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rongyu Liu has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Lei Fang
Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China
12 shared publicationsMuzi Wang
Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China
7 shared publicationsShuai Li
Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China; Intensive Care Unit, The Fourth Affiliated Hospital of Anhui Medical University, Huaihai Avenue 100, Hefei, Anhui 230012, China
7 shared publicationsHuimei Wu
Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China
6 shared publicationsCheng Cheng
Department of Pulmonary, Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, Anhui 230022, China
4 shared publications- Hui-Mei Wu
Department of Geriatric Respiratory and Critical Care Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China; Anhui Geriatric Institute, Hefei, China
4 shared publications
Latest Publications
- 30 April 2023
- Published by The Korean Powder Metallurgy & Materials Institute in Journal of Powder Materials
- Vol. 30 (2) , 101-106
Study on Reaction Behavior of Mg-FeB Phase for Rare Earth Elements Recovery from End-of-life Magnet
- 30 April 2023
- Published by The Korean Powder Metallurgy & Materials Institute in Journal of Powder Materials
- Vol. 30 (2) , 101-106
Study on Reaction Behavior of Mg-FeB Phase for Rare Earth Elements Recovery from End-of-life Magnet
- Open Access
- 14 January 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (2) , 741-746
Occupational fibrotic hypersensitivity pneumonia in a halogen dishes manufacturer: A case report
Fibrotic hypersensitivity pneumonitis (FHP) is an allergic and diffuse pneumonia caused by repeated inhalation of antigenic substances, and sometimes developed in people working in specific environments. While novel antigens and exposures continued to be described, physicians should maintain a high suspicion of potential exposures. A detailed assessment of the patient's occupational exposures as well as living environment is necessary and complete allergen avoidance is the first and most important step in the management of FHP once the allergens are determined. A 35-year-old female was admitted to the hospital with a cough and breathing difficulties for more than one year. She was a nonsmoker and a manufacturer of halogen dishes, which are characteristic Chinese foods, for 15 years without any protection. High resolution computed tomography of the chest demonstrated an interstitial pneumonia pattern. Pulmonary function examination showed restricted ventilation dysfunction and a significant reduction in dispersion ability. Cell differentiation in bronchoalveolar lavage fluid demonstrated lymphocytosis (70.4%) with an increased lymphocyte CD4/CD8 ratio (0.94). Transbronchial lung biopsy combined with lung puncture pathology showed diffuse uniform alveolar interval thickening, chronic inflammatory cell infiltration, a proliferation of tissue in the bronchial wall fiber and alveolar epithelial follicle degeneration, resulting in fibrosis. Exposure to spices used for the production of halogen dishes may cause FHP.
- 14 January 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (2) , 741-746
Open AccessOccupational fibrotic hypersensitivity pneumonia in a halogen dishes manufacturer: A case report
Fibrotic hypersensitivity pneumonitis (FHP) is an allergic and diffuse pneumonia caused by repeated inhalation of antigenic substances, and sometimes developed in people working in specific environments. While novel antigens and exposures continued to be described, physicians should maintain a high suspicion of potential exposures. A detailed assessment of the patient's occupational exposures as well as living environment is necessary and complete allergen avoidance is the first and most important step in the management of FHP once the allergens are determined. A 35-year-old female was admitted to the hospital with a cough and breathing difficulties for more than one year. She was a nonsmoker and a manufacturer of halogen dishes, which are characteristic Chinese foods, for 15 years without any protection. High resolution computed tomography of the chest demonstrated an interstitial pneumonia pattern. Pulmonary function examination showed restricted ventilation dysfunction and a significant reduction in dispersion ability. Cell differentiation in bronchoalveolar lavage fluid demonstrated lymphocytosis (70.4%) with an increased lymphocyte CD4/CD8 ratio (0.94). Transbronchial lung biopsy combined with lung puncture pathology showed diffuse uniform alveolar interval thickening, chronic inflammatory cell infiltration, a proliferation of tissue in the bronchial wall fiber and alveolar epithelial follicle degeneration, resulting in fibrosis. Exposure to spices used for the production of halogen dishes may cause FHP.
- Open Access
- 1 January 2022
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 14 (1) , 85-98
Asthma Management Using the Mobile Asthma Evaluation and Management System in China
Lin J, et al. Allergy Asthma Immunol Res. 2022 Jan;14(1):85-98. https://doi.org/10.4168/aair.2022.14.1.85
- 1 January 2022
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 14 (1) , 85-98
Open AccessAsthma Management Using the Mobile Asthma Evaluation and Management System in China
Lin J, et al. Allergy Asthma Immunol Res. 2022 Jan;14(1):85-98. https://doi.org/10.4168/aair.2022.14.1.85
- 1 September 2020
- Published by Elsevier in Life Sciences
- Vol. 256, 117896
TLR2 favors OVA-induced allergic airway inflammation in mice through JNK signaling pathway with activation of autophagy
- 1 September 2020
- Published by Elsevier in Life Sciences
- Vol. 256, 117896
TLR2 favors OVA-induced allergic airway inflammation in mice through JNK signaling pathway with activation of autophagy
- 1 March 2020
- Published by Elsevier in Toxicology Letters
- Vol. 321, 146-154
Particulate matters induce acute exacerbation of allergic airway inflammation via the TLR2/NF-κB/NLRP3 signaling pathway
- 1 March 2020
- Published by Elsevier in Toxicology Letters
- Vol. 321, 146-154
Particulate matters induce acute exacerbation of allergic airway inflammation via the TLR2/NF-κB/NLRP3 signaling pathway
- Open Access
- 11 August 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (9) , e22990
Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
Background: Lung adenocarcinoma (LUAD) is one of the leading contributors to cancer‐related deaths worldwide. The objective of the current study is to identify a multidimensional transcriptome prognostic signature by combining protein‐coding gene (PCG) with long non‐coding RNA (lncRNA) for patients with LUAD.Methods: We obtained LUAD PCG and lncRNA expression profile data from three datasets in the Gene Expression Omnibus database and conducted survival analyzes for these individuals.Results: We established a predictive model comprising the three PCGs (NHLRC2, PLIN5, GNAI3), and one lncRNA (AC087521.1). This model segregated patients with LUAD into low‐ and high‐risk groups based on significant differences in survival in the training dataset (GSE31210, n = 226, log‐rank test P < .001). Risk stratification of the model was subsequently validated in other two test datasets (GSE37745, n = 106, log‐rank test P < .001; GSE30219, n = 85, log‐rank test P = .006). Time‐dependent receiver operating characteristic (timeROC) curve analysis demonstrated that the model correlated strongly with disease progression and outperformed pathological stage in terms of prognostic ability. Cox proportional hazards regression analysis revealed that the signature could serve as an independent predictor of clinical outcomes in patients with LUAD.Conclusions: We describe a novel multidimensional transcriptome signature that can predict survival probabilities in patients with LUAD.
- 11 August 2019
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 33 (9) , e22990
Open AccessIdentification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
Background: Lung adenocarcinoma (LUAD) is one of the leading contributors to cancer‐related deaths worldwide. The objective of the current study is to identify a multidimensional transcriptome prognostic signature by combining protein‐coding gene (PCG) with long non‐coding RNA (lncRNA) for patients with LUAD.Methods: We obtained LUAD PCG and lncRNA expression profile data from three datasets in the Gene Expression Omnibus database and conducted survival analyzes for these individuals.Results: We established a predictive model comprising the three PCGs (NHLRC2, PLIN5, GNAI3), and one lncRNA (AC087521.1). This model segregated patients with LUAD into low‐ and high‐risk groups based on significant differences in survival in the training dataset (GSE31210, n = 226, log‐rank test P < .001). Risk stratification of the model was subsequently validated in other two test datasets (GSE37745, n = 106, log‐rank test P < .001; GSE30219, n = 85, log‐rank test P = .006). Time‐dependent receiver operating characteristic (timeROC) curve analysis demonstrated that the model correlated strongly with disease progression and outperformed pathological stage in terms of prognostic ability. Cox proportional hazards regression analysis revealed that the signature could serve as an independent predictor of clinical outcomes in patients with LUAD.Conclusions: We describe a novel multidimensional transcriptome signature that can predict survival probabilities in patients with LUAD.
- Open Access
- 4 August 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-9
Alda-1 Prevents Pulmonary Epithelial Barrier Dysfunction following Severe Hemorrhagic Shock through Clearance of Reactive Aldehydes
Severe hemorrhagic shock and resuscitation (HS/R) can lead to lung injury, resulting in respiratory insufficiency. We investigated whether treatment with Alda-1, an ALDH2 activator, decreased lung injury induced by severe HS/R in a rat model. Male Sprague-Dawley rats were randomized into three groups, hemorrhagic shock + placebo, hemorrhagic shock + Alda-1, and sham. All animals were heparinized, and then 50% of the total calculated blood volume was collected over 60 minutes. After 40 minutes of hemorrhagic shock, animals were reinfused with the shed blood over 40 minutes and then observed for an additional 2 hours. Concentrations of 4-HNE, TNF-α, IL-6, and ALDH2 activity were detected; lung injury and lung wet-to-dry weight ratios were assessed. Expression of occludin and ZO-1 proteins in lung tissues was also determined. At 2 hours after resuscitation, lung injury was significantly reduced and the wet-to-dry weight ratio was notably decreased in the Alda-1 group compared with placebo (Pαwere dramatically decreased compared with placebo-treated animals (P<0.05). Expression of occludin and ZO-1 proteins was significantly decreased in the placebo group compared with the Alda-1 group (P<0.05). Thus, in a rat model of severe HS/R, treatment with Alda-1 increased the activity of ALDH2, significantly accelerated the clearance of reactive aldehydes, and concomitantly alleviated lung injury through improvement of pulmonary epithelial barrier integrity resulting in decreased alveolar epithelial tissue permeability, lung edema, and diffuse infiltration of inflammatory cells.
- 4 August 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-9
Open AccessAlda-1 Prevents Pulmonary Epithelial Barrier Dysfunction following Severe Hemorrhagic Shock through Clearance of Reactive Aldehydes
Severe hemorrhagic shock and resuscitation (HS/R) can lead to lung injury, resulting in respiratory insufficiency. We investigated whether treatment with Alda-1, an ALDH2 activator, decreased lung injury induced by severe HS/R in a rat model. Male Sprague-Dawley rats were randomized into three groups, hemorrhagic shock + placebo, hemorrhagic shock + Alda-1, and sham. All animals were heparinized, and then 50% of the total calculated blood volume was collected over 60 minutes. After 40 minutes of hemorrhagic shock, animals were reinfused with the shed blood over 40 minutes and then observed for an additional 2 hours. Concentrations of 4-HNE, TNF-α, IL-6, and ALDH2 activity were detected; lung injury and lung wet-to-dry weight ratios were assessed. Expression of occludin and ZO-1 proteins in lung tissues was also determined. At 2 hours after resuscitation, lung injury was significantly reduced and the wet-to-dry weight ratio was notably decreased in the Alda-1 group compared with placebo (Pαwere dramatically decreased compared with placebo-treated animals (P<0.05). Expression of occludin and ZO-1 proteins was significantly decreased in the placebo group compared with the Alda-1 group (P<0.05). Thus, in a rat model of severe HS/R, treatment with Alda-1 increased the activity of ALDH2, significantly accelerated the clearance of reactive aldehydes, and concomitantly alleviated lung injury through improvement of pulmonary epithelial barrier integrity resulting in decreased alveolar epithelial tissue permeability, lung edema, and diffuse infiltration of inflammatory cells.
- Open Access
- 12 May 2019
- Published by Wiley in Journal of Immunology Research
- Vol. 2019, 1-10
Anti-inflammatory Property of Galectin-1 in a Murine Model of Allergic Airway Inflammation
Galectin-1 (Gal-1) has immunomodulatory activities in various allergic inflammatory disorders, but its potential anti-inflammatory properties on allergic airway diseases have not been confirmed. We explored the pharmacological effects of Gal-1 on the progression of allergic airway inflammation and investigated the underlying mechanism. Female C57BL/6 mice were sensitized on day 0 and challenged with ovalbumin (OVA) on days 14-17 to establish an allergic airway inflammation model. In the challenge phase, a subset of mice was treated intraperitoneally with recombinant Gal-1 (rGal-1) or dexamethasone (Dex). We found that rGal-1 inhibited pulmonary inflammatory cell recruitment, mucus secretion, bronchoalveolar lavage fluid (BALF) inflammatory cell infiltration, and cytokine production. The treatment also suppressed the infiltration of eosinophils into the allergic lung as indicated by decreased expression levels of eotaxin and eosinophil peroxidase (EPX). However, only the expression levels of IL-25, neither IL-33 nor TSLP, were significantly decreased in the lung by rGal-1 treatment. These immunomodulatory effects in the allergic lung were correlated with the activation of extracellular signal-regulated kinase (ERK) signaling pathway and downregulation of endogenous Gal-1. In addition, rGal-1 reduced the plasma concentrations of anti-OVA immunoglobulin E (IgE) and IL-17. Our findings suggest that rGal-1 is an effective therapy for allergic airway inflammation in a murine model and may be a potential pharmacological target for allergic airway inflammatory diseases.
- 12 May 2019
- Published by Wiley in Journal of Immunology Research
- Vol. 2019, 1-10
Open AccessAnti-inflammatory Property of Galectin-1 in a Murine Model of Allergic Airway Inflammation
Galectin-1 (Gal-1) has immunomodulatory activities in various allergic inflammatory disorders, but its potential anti-inflammatory properties on allergic airway diseases have not been confirmed. We explored the pharmacological effects of Gal-1 on the progression of allergic airway inflammation and investigated the underlying mechanism. Female C57BL/6 mice were sensitized on day 0 and challenged with ovalbumin (OVA) on days 14-17 to establish an allergic airway inflammation model. In the challenge phase, a subset of mice was treated intraperitoneally with recombinant Gal-1 (rGal-1) or dexamethasone (Dex). We found that rGal-1 inhibited pulmonary inflammatory cell recruitment, mucus secretion, bronchoalveolar lavage fluid (BALF) inflammatory cell infiltration, and cytokine production. The treatment also suppressed the infiltration of eosinophils into the allergic lung as indicated by decreased expression levels of eotaxin and eosinophil peroxidase (EPX). However, only the expression levels of IL-25, neither IL-33 nor TSLP, were significantly decreased in the lung by rGal-1 treatment. These immunomodulatory effects in the allergic lung were correlated with the activation of extracellular signal-regulated kinase (ERK) signaling pathway and downregulation of endogenous Gal-1. In addition, rGal-1 reduced the plasma concentrations of anti-OVA immunoglobulin E (IgE) and IL-17. Our findings suggest that rGal-1 is an effective therapy for allergic airway inflammation in a murine model and may be a potential pharmacological target for allergic airway inflammatory diseases.
- 24 April 2019
- Published by Wiley in IUBMB Life
- Vol. 71 (7) , 1021-1029
Melatonin enhances autophagy and decreases apoptosis induced by nanosilica in RAW264.7 cells
Melatonin is one of the main hormones that regulate biological rhythms and have immunomodulation, anti‐inflammatory, and antioxidation functions. In this study, we aimed to explore the effect of melatonin on the autophagy, apoptosis, and inflammatory reaction of macrophages (RAW264.7 cells) stimulated by nanosilica. SiO2 (100 mg/mL, 10–20 nm) was used to stimulate RAW264.7 cells at different time points (0, 2, 4, 8, 12, and 24 hr). Melatonin (200 μM) was added to SiO2‐stimulated macrophages at 12 hr. Beclin‐1, LC3, Bax, Bcl‐2, and Caspase‐3 were examined with western blotting. Flow cytometry was used to detect apoptosis. The levels of TNF‐α, IL‐1β, and IL‐18 were detected by ELISA. The level of TNF‐α in the supernatant of SiO2‐stimulated cells gradually increased with time but decreased following melatonin administration. In contrast, the expression of IL‐1β and IL‐18 increased after melatonin treatment. LC3 and Bax signaling pathways were activated in SiO2‐stimulated RAW264.7 cells, showing elevated expression of LC3 and reduced expression of Bax in the melatonin‐treated cells. GFP‐LC3 puncta were significantly increased in SiO2‐stimulated RAW264.7 cells and decreased in melatonin‐treated cells. The apoptotic rate in SiO2‐stimulated RAW264.7 cells increased with time and decreased after melatonin treatment, and the number of phagosomes increased with the stimulation of nanosilica and the treatment of melatonin. Melatonin might promote autophagy and inhibit apoptosis as well as inflammatory responses of RAW264.7 cells stimulated by nanosilica. © 2019 IUBMB Life, 2019
- 24 April 2019
- Published by Wiley in IUBMB Life
- Vol. 71 (7) , 1021-1029
Melatonin enhances autophagy and decreases apoptosis induced by nanosilica in RAW264.7 cells
Melatonin is one of the main hormones that regulate biological rhythms and have immunomodulation, anti‐inflammatory, and antioxidation functions. In this study, we aimed to explore the effect of melatonin on the autophagy, apoptosis, and inflammatory reaction of macrophages (RAW264.7 cells) stimulated by nanosilica. SiO2 (100 mg/mL, 10–20 nm) was used to stimulate RAW264.7 cells at different time points (0, 2, 4, 8, 12, and 24 hr). Melatonin (200 μM) was added to SiO2‐stimulated macrophages at 12 hr. Beclin‐1, LC3, Bax, Bcl‐2, and Caspase‐3 were examined with western blotting. Flow cytometry was used to detect apoptosis. The levels of TNF‐α, IL‐1β, and IL‐18 were detected by ELISA. The level of TNF‐α in the supernatant of SiO2‐stimulated cells gradually increased with time but decreased following melatonin administration. In contrast, the expression of IL‐1β and IL‐18 increased after melatonin treatment. LC3 and Bax signaling pathways were activated in SiO2‐stimulated RAW264.7 cells, showing elevated expression of LC3 and reduced expression of Bax in the melatonin‐treated cells. GFP‐LC3 puncta were significantly increased in SiO2‐stimulated RAW264.7 cells and decreased in melatonin‐treated cells. The apoptotic rate in SiO2‐stimulated RAW264.7 cells increased with time and decreased after melatonin treatment, and the number of phagosomes increased with the stimulation of nanosilica and the treatment of melatonin. Melatonin might promote autophagy and inhibit apoptosis as well as inflammatory responses of RAW264.7 cells stimulated by nanosilica. © 2019 IUBMB Life, 2019
- 3 April 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (11) , 19990-20001
NLRC5 negatively regulates LTA‐induced inflammation via TLR2/NF‐κB and participates in TLR2‐mediated allergic airway inflammation
NLRC5, the largest member of the Nod‐like receptor (NLR) family, has been reported to play a pivotal role in regulating inflammatory responses. Recent evidence suggests that NLRC5 participates in Toll‐like receptor (TLR) signaling pathways and negatively modulates nuclear factor‐κB (NF‐κB) activation. In this study, we investigated the interaction between NLRC5 and TLR2 in the NF‐κB inflammatory signaling pathway and the involvement of NLRC5 in TLR2‐mediated allergic airway inflammation. We knocked down TLR2 and NLRC5, respectively in the RAW264.7 macrophage cell line by small interfering RNA (siRNA) and then stimulated the knockdown cells with lipoteichoic acid (LTA). In comparison with the negative siRNA group, the level of NLRC5 expression was lower in the TLR2 siRNA group, with a reduction in the NF‐κB‐related inflammatory response. Conversely, in the NLRC5 knockdown cells, after LTA‐treated the level of TLR2 expression did not change but the expression levels of both NF‐κB pp65 and NLRP3 increased remarkably. Thus, we hypothesize that NLRC5 participates in the LTA‐induced inflammatory signaling pathway and regulates the inflammation via TLR2/NF‐κB. Similarly, in subsequent in vivo experiments, we demonstrated that the expression level of NLRC5 was significantly increased in the ovalbumin‐induced allergic airway inflammation. However, this effect disappeared in TLR2‐deficient (TLR2 −/−) mice and was accompanied by reduced levels of NF‐κB expression and airway inflammation. In conclusion, NLRC5 negatively regulates LTA‐induced inflammatory response via a TLR2/NF‐κB pathway in macrophages and also participates in TLR2‐mediated allergic airway inflammation.
- 3 April 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (11) , 19990-20001
NLRC5 negatively regulates LTA‐induced inflammation via TLR2/NF‐κB and participates in TLR2‐mediated allergic airway inflammation
NLRC5, the largest member of the Nod‐like receptor (NLR) family, has been reported to play a pivotal role in regulating inflammatory responses. Recent evidence suggests that NLRC5 participates in Toll‐like receptor (TLR) signaling pathways and negatively modulates nuclear factor‐κB (NF‐κB) activation. In this study, we investigated the interaction between NLRC5 and TLR2 in the NF‐κB inflammatory signaling pathway and the involvement of NLRC5 in TLR2‐mediated allergic airway inflammation. We knocked down TLR2 and NLRC5, respectively in the RAW264.7 macrophage cell line by small interfering RNA (siRNA) and then stimulated the knockdown cells with lipoteichoic acid (LTA). In comparison with the negative siRNA group, the level of NLRC5 expression was lower in the TLR2 siRNA group, with a reduction in the NF‐κB‐related inflammatory response. Conversely, in the NLRC5 knockdown cells, after LTA‐treated the level of TLR2 expression did not change but the expression levels of both NF‐κB pp65 and NLRP3 increased remarkably. Thus, we hypothesize that NLRC5 participates in the LTA‐induced inflammatory signaling pathway and regulates the inflammation via TLR2/NF‐κB. Similarly, in subsequent in vivo experiments, we demonstrated that the expression level of NLRC5 was significantly increased in the ovalbumin‐induced allergic airway inflammation. However, this effect disappeared in TLR2‐deficient (TLR2 −/−) mice and was accompanied by reduced levels of NF‐κB expression and airway inflammation. In conclusion, NLRC5 negatively regulates LTA‐induced inflammatory response via a TLR2/NF‐κB pathway in macrophages and also participates in TLR2‐mediated allergic airway inflammation.